Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Parabilis Medicines's pretax income for the
six
months ended in Dec. 2025 was $-145.89 Mil.
Parabilis Medicines does not have enough years/quarters to calculate the pretax income for the trailing twelve months (TTM) ended in Dec. 2025.
Parabilis Medicines's pretax margin was %.
Parabilis Medicines (NAS:PBLS) Pre-Tax Income Explanation
Parabilis Medicines's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Pre-Tax Income Related Terms
Parabilis Medicines Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Pre-Tax Income Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Pre-Tax Income
-117.91
-145.89
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Pre-Tax Income
-117.91
-145.89
PBLS vs IDYA, ELVN, BEAM: Pre-Tax Income Comparison
For the Biotechnology subindustry, Parabilis Medicines's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Pre-Tax Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Pre-Tax Income of $ Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Parabilis Medicines and its competitors.
Is Parabilis Medicines' Pre-Tax Income too high?
Parabilis Medicines' current Pre-Tax Income is $ Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Pre-Tax Income compare to IDYA and ELVN?
Parabilis Medicines' Pre-Tax Income of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Pre-Tax Income is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Pre-Tax Income of $ Mil. The current Pre-Tax Income is $ Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Pre-Tax Income is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
